 "Dr Reddy's launches cholesterol-lowering Colesevelam HCl tablets in US")
Dr Reddy's Laboratories Limited announced on Tuesday that it has launched cholesterol lowering Colesevelam HCl Tablets, a therapeutic equivalent generic version of Welchol Tablets, in the US market.
The company's abbreviated new drug application (ANDA) for this product was recently approved by the US Food and Drug Administration (US FDA).
The Welchol brand, which is a registered trademark of Daiichi Sankyo, Inc, and generics had US sales of approximately $471 million for the most recent twelve months ending in August 2018, the company said, while quoting the IMS Health data.
Dr Reddy's Colesevelam Hydrochloride tablets is available in 625 mg with 180-count bottle size, according to the press release.
Other companies, namely Alkem Labs, Glenmark Pharmaceuticals and Impax Labs were also granted product approval to manufacture and market Colesevelam HCl tablets by the US drug regulator.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%